HOUSTON, Sept. 14, 2026 (GLOBE NEWSWIRE) — This corrected press release is being issued to correct the merger exchange ratio that was incorrectly stated in the press release of Impact Biomedical Inc. (the “Company” or “Impact”) dated September 11, 2026. The original press release incorrectly stated that Impact stockholders would receive one (1) share of Zoar Limited for every four (4) shares of Impact Common Stock (defined below). The correct exchange ratio, as set forth in the Merger and Share Exchange Agreement as Exhibit 2.1 to the current report on Form 8-K dated June 23, 2025 (Accession No.0001641172-25-016002), is one (1) share of Zoar Limited for every one (1) share of Impact Common Stock held immediately prior to the effective time of the merger, after giving effect to the Reverse Stock Split. No other changes have been made to the original press release.

The Company today announced that the Company’s Board of Directors has approved a 1 for 12.62 reverse stock split of the Company’s issued and outstanding common stock, par value $0.001 per share (the “Common Stock”). The reverse stock split will become effective at 12:01 a.m., Eastern Time, on September 23, 2026. Starting with the opening of trading on that date, the Company’s Common Stock will continue to trade on the NYSE American Exchange under the ticker symbol “IBO” and will trade under a new CUSIP number to be assigned in connection with the reverse stock split.

On December 30, 2025, the Company’s stockholders approved a second reverse stock split of the Company’s Common Stock at a ratio of not less than 1-for-12.48 and not more than 1-for-50 to be implemented at the discretion of the Chief Executive Officer. The Reverse Stock Split is intended to support the Company’s efforts in connection with the proposed business combination transaction and its continued-listing objectives. The Reverse Stock Split does not assure that the Company will satisfy applicable NYSE American continued-listing standards, obtain approval of any applicable listing application, or complete the proposed transaction.

The merger of Impact Biomedical Inc. and Zoar, upon approval and closing, is expected to result in a pharmaceutical company focused on the development and supply of Active Pharmaceutical Ingredients and intermediates for special therapeutic treatment areas.

Read the original merger announcement here: https://www.sec.gov/Archives/edgar/data/1834105/000164117225016002/ex99-1.htm

Upon completion of the proposed merger, Impact stockholders are expected to receive one (1) share of Zoar Limited for every one (1) share of Impact Common Stock held immediately prior to the effective time of the merger, after giving effect to the Reverse Stock Split.

 
 

The reverse stock split will combine every 12.62 shares of the Company’s issued and outstanding Common Stock into one (1) new share of Common Stock. No fractional shares will be issued in connection with the Reverse Stock Split. Stockholders who would otherwise be entitled to receive a fractional share will have their fractional share rounded up to the next whole share. Other than adjustments resulting from the treatment of fractional shares, the Reverse Stock Split will affect all stockholders uniformly and will not alter any stockholder’s percentage ownership interest in the Company.

Stockholders holding shares in book-entry form or through a bank, broker, or other nominee do not need to take any action. Impact Biomedical’s transfer agent, Equiniti Trust Company, LLC (“Equiniti”), will manage the exchange. Stockholders of record who hold physical certificates will receive a letter of transmittal from Equiniti with instructions for exchanging their shares. Unless a stockholder specifically requests new paper certificates (or holds restricted shares), new shares will be issued electronically in book-entry form.

Following the reverse stock split, the total number of shares of Common Stock outstanding is expected to decrease from approximately 107,821,231 to 8,543,679 subject to minor adjustments due to rounding. Corresponding proportional adjustments will also be made to:

  ● Outstanding equity awards and related exercise prices
     
  ● Shares available under equity incentive plans
     
  ● Other relevant share-based agreements

The reverse stock split will not affect the total number of authorized shares, and all resulting shares will remain fully paid and non-assessable.

Additional information about the reverse stock split can be found in the Company’s definitive information statement filed with the Securities and Exchange Commission (the “SEC”) on December 30, 2025, which is available free of charge at the SEC’s website, www.sec.gov.

Additional Information and Where to Find It

In connection with the proposed transaction, Zoar Limited has filed with the SEC a registration statement on Form F-4 Registration Statement (the “Registration Statement”) that includes a preliminary proxy statement/prospectus (a “Proxy Statement/Prospectus”). After the Registration Statement is declared effective, a definitive Proxy Statement/Prospectus will be mailed to Impact’s stockholders as of a record date to be established by Impact’s board of directors for voting on the proposed merger. Impact may also file other relevant documents regarding the proposed merger with the SEC. Impact’s stockholders and other interested persons are advised to read, once available, the preliminary Proxy Statement/Prospectus and any amendments thereto and, once available, the definitive Proxy Statement/Prospectus, in connection with Impact’s solicitation of proxies for its special meeting of stockholders to be held to approve, among other things, the Business Combination, because these documents will contain important information about Impact, Zoar Labs, PubCo and the proposed merger. Stockholders of Impact may also obtain a copy of the preliminary or definitive Proxy Statement, once available, as well as other documents filed with the SEC regarding the proposed merger and other documents filed with the SEC, without charge, at the SEC’s website located at www.sec.gov or by directing a request to: Impact’s Chief Executive Officer at 1400 Broadfield Blvd., Suite 130, Houston, TX.

Participants in the Solicitation

Impact, PubCo, Zoar Labs, and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from Impact stockholders in connection with the proposed merger. Information about Impact’s directors and executive officers is set forth in Impact’s filings with the SEC. Additional information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, is contained in the Registration Statement and the proxy statement/prospectus included therein.

About Zoar Limited:

Zoar Ltd. is a global pharmaceutical company focused on the development and manufacturing of active pharmaceutical ingredients, formulations, orphan drugs, and contract development and manufacturing services for pharmaceutical and biotechnology companies worldwide.

About IBO:

Impact Biomedical Inc. discovers, confirms, and patents unique science and technologies which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships.

Safe Harbor Disclosure:

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are subject to risks and uncertainties that may cause actual results or events to differ materially from those projected. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date.

Investor Relations:

info@impactbiomedinc.com
www.impactbiomedinc.com

HOUSTON, Sept. 14, 2026 (GLOBE NEWSWIRE) — This corrected press release is being issued to correct the merger exchange ratio that was incorrectly stated in the press release of Impact Biomedical Inc. (the “Company” or “Impact”) dated September 11, 2026. The original press release incorrectly stated that Impact stockholders would receive one (1) share of Zoar Limited for every four (4) shares of Impact Common Stock (defined below). The correct exchange ratio, as set forth in the Merger and Share Exchange Agreement as Exhibit 2.1 to the current report on Form 8-K dated June 23, 2025 (Accession No.0001641172-25-016002), is one (1) share of Zoar Limited for every one (1) share of Impact Common Stock held immediately prior to the effective time of the merger, after giving effect to the Reverse Stock Split. No other changes have been made to the original press release.

The Company today announced that the Company’s Board of Directors has approved a 1 for 12.62 reverse stock split of the Company’s issued and outstanding common stock, par value $0.001 per share (the “Common Stock”). The reverse stock split will become effective at 12:01 a.m., Eastern Time, on September 23, 2026. Starting with the opening of trading on that date, the Company’s Common Stock will continue to trade on the NYSE American Exchange under the ticker symbol “IBO” and will trade under a new CUSIP number to be assigned in connection with the reverse stock split.

On December 30, 2025, the Company’s stockholders approved a second reverse stock split of the Company’s Common Stock at a ratio of not less than 1-for-12.48 and not more than 1-for-50 to be implemented at the discretion of the Chief Executive Officer. The Reverse Stock Split is intended to support the Company’s efforts in connection with the proposed business combination transaction and its continued-listing objectives. The Reverse Stock Split does not assure that the Company will satisfy applicable NYSE American continued-listing standards, obtain approval of any applicable listing application, or complete the proposed transaction.

The merger of Impact Biomedical Inc. and Zoar, upon approval and closing, is expected to result in a pharmaceutical company focused on the development and supply of Active Pharmaceutical Ingredients and intermediates for special therapeutic treatment areas.

Read the original merger announcement here: https://www.sec.gov/Archives/edgar/data/1834105/000164117225016002/ex99-1.htm

Upon completion of the proposed merger, Impact stockholders are expected to receive one (1) share of Zoar Limited for every one (1) share of Impact Common Stock held immediately prior to the effective time of the merger, after giving effect to the Reverse Stock Split.

 
 

The reverse stock split will combine every 12.62 shares of the Company’s issued and outstanding Common Stock into one (1) new share of Common Stock. No fractional shares will be issued in connection with the Reverse Stock Split. Stockholders who would otherwise be entitled to receive a fractional share will have their fractional share rounded up to the next whole share. Other than adjustments resulting from the treatment of fractional shares, the Reverse Stock Split will affect all stockholders uniformly and will not alter any stockholder’s percentage ownership interest in the Company.

Stockholders holding shares in book-entry form or through a bank, broker, or other nominee do not need to take any action. Impact Biomedical’s transfer agent, Equiniti Trust Company, LLC (“Equiniti”), will manage the exchange. Stockholders of record who hold physical certificates will receive a letter of transmittal from Equiniti with instructions for exchanging their shares. Unless a stockholder specifically requests new paper certificates (or holds restricted shares), new shares will be issued electronically in book-entry form.

Following the reverse stock split, the total number of shares of Common Stock outstanding is expected to decrease from approximately 107,821,231 to 8,543,679 subject to minor adjustments due to rounding. Corresponding proportional adjustments will also be made to:

  ● Outstanding equity awards and related exercise prices
     
  ● Shares available under equity incentive plans
     
  ● Other relevant share-based agreements

The reverse stock split will not affect the total number of authorized shares, and all resulting shares will remain fully paid and non-assessable.

Additional information about the reverse stock split can be found in the Company’s definitive information statement filed with the Securities and Exchange Commission (the “SEC”) on December 30, 2025, which is available free of charge at the SEC’s website, www.sec.gov.

Additional Information and Where to Find It

In connection with the proposed transaction, Zoar Limited has filed with the SEC a registration statement on Form F-4 Registration Statement (the “Registration Statement”) that includes a preliminary proxy statement/prospectus (a “Proxy Statement/Prospectus”). After the Registration Statement is declared effective, a definitive Proxy Statement/Prospectus will be mailed to Impact’s stockholders as of a record date to be established by Impact’s board of directors for voting on the proposed merger. Impact may also file other relevant documents regarding the proposed merger with the SEC. Impact’s stockholders and other interested persons are advised to read, once available, the preliminary Proxy Statement/Prospectus and any amendments thereto and, once available, the definitive Proxy Statement/Prospectus, in connection with Impact’s solicitation of proxies for its special meeting of stockholders to be held to approve, among other things, the Business Combination, because these documents will contain important information about Impact, Zoar Labs, PubCo and the proposed merger. Stockholders of Impact may also obtain a copy of the preliminary or definitive Proxy Statement, once available, as well as other documents filed with the SEC regarding the proposed merger and other documents filed with the SEC, without charge, at the SEC’s website located at www.sec.gov or by directing a request to: Impact’s Chief Executive Officer at 1400 Broadfield Blvd., Suite 130, Houston, TX.

Participants in the Solicitation

Impact, PubCo, Zoar Labs, and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from Impact stockholders in connection with the proposed merger. Information about Impact’s directors and executive officers is set forth in Impact’s filings with the SEC. Additional information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, is contained in the Registration Statement and the proxy statement/prospectus included therein.

About Zoar Limited:

Zoar Ltd. is a global pharmaceutical company focused on the development and manufacturing of active pharmaceutical ingredients, formulations, orphan drugs, and contract development and manufacturing services for pharmaceutical and biotechnology companies worldwide.

About IBO:

Impact Biomedical Inc. discovers, confirms, and patents unique science and technologies which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships.

Safe Harbor Disclosure:

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are subject to risks and uncertainties that may cause actual results or events to differ materially from those projected. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date.

Investor Relations:

info@impactbiomedinc.com
www.impactbiomedinc.com

VANCOUVER, British Columbia, Sept. 14, 2026 (GLOBE NEWSWIRE) — DMG Blockchain Solutions Inc. (TSX-V: DMGI) (OTCQB US: DMGGF) (FRANKFURT: 6AX) (“DMG”), a vertically integrated data center and digital assets technology company, today provides an update on the conversion of its Christina Lake, British Columbia data center facility to offer artificial intelligence (AI) colocation services. DMG continues to work towards a definitive agreement on its letter of intent for 50 megawatts of critical IT load AI colocation services. DMG is making progress on the execution portion of the project, which is integral to confirming the construction timeline and operational commitment that is part of the definitive agreement. If and when the definitive agreement is executed in connection with the proposed AI colocation services transaction, DMG will issue a more comprehensive news release disclosing further details of the proposed transaction.

Current update highlights are:

  • Power: seventy-five megawatts confirmed – DMG has completed the contract for an additional 10 megawatts of non-firm power. In total, DMG has 60 megawatts of non-firm power along with 15 megawatts of firm power, totaling 75 megawatts. Our Christina Lake substation, which is DMG-owned, already supports the full 75 megawatt load. DMG is now investigating twinning the main transformer for future expansion and redundancy.
    • Potential for greater than 50 megawatts of critical IT load – we believe we may be able to support greater than 50 megawatts, as our 75 megawatts of total power allows for a worst case power usage effectiveness (PUE) of 1.5. Christina Lake weather conditions, a new generation of servers and the ability to leverage alternative energy sources for chillers all potentially allow us to raise the amount of critical IT load from 50 megawatts.
    • Future: Up to 150 megawatts of firm power – previously, DMG disclosed it has submitted an application with our utility for 150 megawatts of firm power, which is likely to involve a significant capital expense. Subsequent to executing our definitive agreement, we expect to move this process forward. We may be able to combine this firm power with our 60 megawatts of non-firm power depending on our utility’s transmission capacity.
  • Site Progress : DMG has accelerated its efforts on design-build and contractors.
    • General contractor (GC) – we plan to utilize a GC and are in the latter stages of selecting one with data center experience.
    • Design engineering firms – we plan to utilize the electrical engineering firm that we have worked with for the past decade. We have already selected an architectural firm, which has supported us with the permit for our building extension. For mechanical engineering, we are currently deciding among several candidates, all of which have deep cooling systems knowledge with a strong base in British Columbia.
    • Tradesmen – the British Columbia lower interior region where we are located has a good supply of tradesmen. We have secured a few electrical firms as a start, and we know we will need more. In addition, we will look to balance the amount of labor that is incorporated into prefabbed assemblies versus building on-site so as to optimize lead-time, assembly time and cost.
    • Connectivity – we have contracted with two telecom providers for two diverse paths of 100 Gbps fiber to our facility, and we are evaluating a possible third line. These lines may be upgraded to 400 Gbps in the future. Given the remoteness of our site, connectivity has been one of our bigger long lead-time concerns and is an area where we have committed material capital expenditures ahead of a definitive agreement.
  • Site Location: DMG continues working with the local and regional authorities.
    • Permitting – DMG has applied for a permit to construct an addition to our current building, which would approximately double its capacity to support as much as 60 megawatts of critical IT load.
    • Zoning – For many years, DMG has operated in an approved data center-zoned location.
    • Community relations – while we have encountered opposition from a few members of the local community, who were also opposed to DMG in the past as a crypto miner, we have been open and cooperative. We have emphasized that our project will not negatively impact utility rates, while using less water and generating less noise than Bitcoin mining.
  • Timeline: Goal to have tenant servers operating by the end of the year – this was always communicated on a commercially reasonable efforts basis and was predicated in part on quickly reaching a definitive agreement. As we are now in September, we are realistically looking towards a 2027 energization schedule for tenant servers.

In terms of financing this project, DMG is exploring through discussions with multiple financial institutions, a range of instruments, including rated bonds, lines of credit and equity/convertible debt. Our goal is to optimize for cost of capital, flexibility and speed while minimizing dilution. We will update the market if and when terms are finalized.

DMG’s CEO, Sheldon Bennett, commented, “We are pleased with our continued progress towards our goal of converting our Christina Lake facility to an AI data center to offer colocation services to a long-term tenant. Concurrently, we are laying the track for future sites, as we believe DMG can become a leader in Canada for offering AI data center colocation services, given our experience working with utilities and connecting to large amounts of power as well as our early position to build a major AI data center site.”

There is no assurance that the AI colocation services definitive agreement will be successfully negotiated or executed by the parties. In addition, the conversion of the Christina Lake, British Columbia data center facility to offer artificial intelligence (AI) colocation services is subject to several conditions, including but not limited to, financing, permitting and entering into agreements with counterparties that are necessary to complete the conversion of the Bitcoin data center to an AI colocation data center.

DMG Management at H.C. Wainwright Global Investment Conference

Company management will present at the H.C. Wainwright 28th Annual Global Investment Conference, September 14-16, at the Lotte New York Palace in New York City. The company’s presentation is scheduled for Tuesday, September 15, at 9:00 AM ET.

About DMG Blockchain Solutions Inc.

DMG is a sustainable, vertically integrated data center and digital asset technology company that develops, manages and operates comprehensive platform solutions to monetize the artificial intelligence (AI) and blockchain ecosystems. The Company’s operations are driven by two strategic pillars: Data Center Infrastructure (Core) and Digital Asset Software and Services (Core+). DMG is expanding its platform to include AI and sovereign compute solutions, supporting government, enterprise and research organizations across Canada.

For more information on DMG Blockchain Solutions visit: www.dmgblockchain.com
Follow @dmgblockchain on X and subscribe to DMG’s YouTube channel.

For further information, please contact:

On behalf of the Board of Directors,

Sheldon Bennett, CEO & Director
Tel: +1 (778) 300-5406
Email: investors@dmgblockchain.com
Web: www.dmgblockchain.com

For Investor Relations:
investors@dmgblockchain.com

For Media Inquiries:
communications@dmgblockchain.com

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Cautionary Note Regarding Forward-Looking Information

This news release contains forward-looking information or statements based on current expectations. Forward-looking statements contained in this news release include potential AI opportunities, the Company’s plan to convert its Christina Lake data center into an AI data center and the expected timelines, entering into a definitive agreement with a potential tenant to offer 50 megawatts of AI data center colocation services at the Christina Lake facility, the Company’s strategy for growth, the planned monetization of certain product and service offerings, developing and executing on the Company’s products, services and business plans, the launch of products and services, events, courses of action, and the potential of the Company’s technology and operations, among others, are all forward-looking information. Completion of the proposed transaction is subject to a number of conditions, including entering into the definitive agreement.

Future changes in the Bitcoin network-wide mining difficulty rate or Bitcoin hashrate may materially affect the future performance of DMG’s production of bitcoin, and future operating results could also be materially affected by the price of bitcoin and an increase in hashrate mining difficulty.

Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations, or intentions regarding the future. Such information can generally be identified by the use of forward-looking wording such as “may”, “expect”, “estimate”, “anticipate”, “intend”, “believe” and “continue” or the negative thereof or similar variations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including but not limited to, market and other conditions, volatility in the trading price of the common shares of the Company, business, economic and capital market conditions; the ability to manage operating expenses, which may adversely affect the Company’s financial condition; the ability to remain competitive as other better-financed competitors develop and release competitive products; regulatory uncertainties; access to equipment; market conditions and the demand and pricing for products; the demand and pricing of bitcoin; the demand and pricing of AI data centers and usage; security threats, including a loss/theft of DMG’s bitcoin; DMG’s relationships with its customers, distributors and business partners; the inability to add more power to DMG’s facilities; DMG’s ability to successfully define, design and release new products in a timely manner that meet customers’ needs; the ability to attract, retain and motivate qualified personnel; competition in the industry; the impact of technology changes on the products and industry; failure to develop new and innovative products; the ability to successfully maintain and enforce our intellectual property rights and defend third-party claims of infringement of their intellectual property rights; the impact of intellectual property litigation that could materially and adversely affect the business; the ability to manage working capital; and the dependence on key personnel. DMG may not actually achieve its plans, projections, or expectations. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which the Company will operate in the future, including the demand for its products and services, the ability to successfully develop software, that there will be no regulation or law that will prevent the Company from operating its business, anticipated costs, the ability to secure sufficient capital to complete its business plans, the ability to achieve goals and the price of bitcoin. Given these risks, uncertainties, and assumptions, you should not place undue reliance on these forward-looking statements. The securities of DMG are considered highly speculative due to the nature of DMG’s business. For further information concerning these and other risks and uncertainties, refer to the Company’s filings on www.sedarplus.ca. In addition, DMG’s past financial performance may not be a reliable indicator of future performance.

Factors that could cause actual results to differ materially from those in forward-looking statements include failure to obtain regulatory approval, the continued availability of capital and financing, equipment and/or infrastructure failures, lack of supply of equipment, power and infrastructure, failure to obtain any permits required to operate the business, the impact of technology changes on the industry, the impact of viruses and diseases on the Company’s ability to operate, secure equipment, and hire personnel, competition, security threats including stolen bitcoin from DMG or its customers, consumer sentiment towards DMG’s products, services, and AI and blockchain technology generally, failure to develop new and innovative products, litigation, lack of demand for the Company’s products and services, adverse weather or climate events, increase in operating costs, increase in equipment and labor costs, equipment failures, decrease in the price of Bitcoin, failure of counterparties to perform their contractual obligations, government regulations, loss of key employees and consultants, and general economic, market or business conditions. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The reader is cautioned not to place undue reliance on any forward-looking information. The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Additionally, the Company undertakes no obligation to comment on the expectations of or statements made by third parties in respect of the matters discussed above.

CALGARY, Alberta, Sept. 14, 2026 (GLOBE NEWSWIRE) — Questor Technology Inc. (“Questor” or the “Company”) (TSX-V: QST) announces that Aly Sumar has resigned as the Company’s Chief Financial Officer and Corporate Secretary. During the transition period, the Audit Committee of the Board of Directors will provide oversight while the Company conducts a search for a permanent Chief Financial Officer.

ABOUT QUESTOR TECHNOLOGY INC.

Questor Technology Inc., incorporated in Canada under the Business Companies Act (Alberta), is an environmental emissions reduction technology company founded in 1994, with global operations. The Company is focused on clean air technologies that safely and cost effectively improve air quality, support energy efficiency and greenhouse gas emission reductions. The Company designs, manufactures and services high efficiency clean combustion systems that destroy harmful pollutants, including Methane, Hydrogen Sulfide gas, Volatile Organic Hydrocarbons, Hazardous Air Pollutants and BTEX (Benzene, Toluene, Ethylbenzene and Xylene) gases within waste gas streams at 99.99 percent efficiency per its ISO 14034 Certification.

The Company also has proprietary heat to power generation technology and is currently targeting new markets including landfill biogas, syngas, waste engine exhaust, geothermal and solar, cement plant waste heat in addition to a wide variety of oil and gas projects. The combination of Questor’s clean combustion and power generation technologies can help clients achieve net zero emission targets for minimal cost.

QUESTOR TRADES ON THE TSX VENTURE EXCHANGE UNDER THE SYMBOL ‘QST’

For further information, please contact:

Mike Lindsay
Interim President and Chief Executive Officer
Phone: 403-571-1530

Email: mlindsay@questortech.com

Investor Relations Contact:
Email: investor@questortech.com

Forward-Looking Statements

Certain information in this news release constitutes forward-looking statements. When used in this news release, the words “may”, “would”, “could”, “will”, “intend”, “plan”, “anticipate”, “believe”, “seek”, “propose”, “estimate”, “expect”, and similar expressions, as they relate to the Company, are intended to identify forward-looking statements. This news release contains forward-looking statements with respect to, among other things, business objectives, expected growth, results of operations, performance, business projects and opportunities and financial results. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements. Such statements reflect the Company’s current views with respect to future events based on certain material factors and assumptions and are subject to certain risks and uncertainties, including without limitation, changes in market, competition, governmental or regulatory developments, general economic conditions and other factors set out in the Company’s public disclosure documents. Many factors could cause the Company’s actual results, performance or achievements to vary from those described in this news release, including without limitation those listed above. These factors should not be construed as exhaustive. Should one or more of these risks or uncertainties materialize, or should assumptions underlying forward-looking statements prove incorrect, actual results may vary materially from those described in this news release and such forward-looking statements included in, or incorporated by reference in this news release, should not be unduly relied upon. Such statements speak only as of the date of this news release. The Company does not intend, and does not assume any obligation, to update these forward-looking statements. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This document is not intended for dissemination or distribution in the United States.

SALT LAKE CITY, Sept. 14, 2026 (GLOBE NEWSWIRE) — Health Catalyst, Inc. (“Health Catalyst” or the “Company,” Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health systems, today announced that on September 14, 2026, the Compensation Committee of the Company’s Board of Directors granted 2,747,385 restricted stock units (the “RSUs”) to Simeon Kohl under the Health Catalyst, Inc. 2026 Employment Inducement Incentive Plan (the “Inducement Plan”) in connection with Mr. Kohl’s previously announced appointment as Chief Executive Officer and President of the Company effective on September 14, 2026. The awards were granted as inducement material to Mr. Kohl’s entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

Of the 2,747,385 RSUs granted to Mr. Kohl, 915,975 RSUs will vest on September 14, 2027 and the remaining RSUs will vest in eight approximately equal quarterly installments, in each case subject to Mr. Kohl’s continued employment with the Company on such vesting date. The awards are subject to the terms and conditions of the Inducement Plan and the terms and conditions of the RSU agreement covering the grant.

The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees or directors of the Company or its subsidiaries, or following a bona fide period of non-employment, as an inducement material to such individuals’ entering into employment with the Company, pursuant to Nasdaq Listing Rule 5635(c)(4).

On September 11, 2026 and September 14, 2026, Mr. Kohl acquired an aggregate of 59,000 shares of Health Catalyst’s common stock through open market purchases with a weighted average price of $1.787188 per share.

About Health Catalyst

Health Catalyst, Inc. (Nasdaq: HCAT) is a healthcare intelligence company designed to accelerate measurable improvement for health systems across cost, clinical, and consumer performance. Backed by deep domain expertise, proprietary AI-driven technology, and $2.8 billion in documented outcomes, Health Catalyst helps health systems move from data to confident, measurable action.

Health Catalyst Investor Relations Contact
Stephanie St. Clair
Finance and Investor Relations, SVP
+1 (855)-309-6800
ir@healthcatalyst.com

Health Catalyst Media Contact
Kay Blazar
VP, PR
SVM PR & Marketing
Healthcatalyst@SVMPR.com

New executive role places dedicated expertise behind Five Star Bank’s commitment to listen, partner, and respond to communities across California

RANCHO CORDOVA, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) — Five Star Bancorp (Nasdaq: FSBC) (“Five Star” or the “Company”), a holding company that operates through its wholly owned banking subsidiary, Five Star Bank, today announced the appointment of Lydia Ramirez as Executive Vice President / Chief External Affairs Officer, a newly created role that puts dedicated professional leadership behind the bank’s commitment to community. Ramirez will help ensure local priorities directly inform how Five Star serves clients, invests in partnerships, and grows across California.

Ramirez will lead Five Star’s enterprise-wide external affairs strategy and serve as a direct connection among the bank, its clients, and community partners in current and future markets. Her mandate is clear: listen to local voices, identify evolving needs, and translate those insights into responsive partnerships and meaningful action. The appointment reflects Five Star’s belief that responsible growth begins with understanding—and being accountable to—the communities it serves. This new role follows a string of expansions for Five Star Bank over the past year. Recent expansions to Lodi, Southern California, and Walnut Creek have solidified its growing footprint across the Golden State.

“Our commitment to community must be visible in how we listen, where we invest, and how we act,” said James Beckwith, President and CEO of Five Star. “Creating this role and appointing a trusted professional like Lydia puts expertise, leadership, and accountability behind that commitment. As we continue to expand, Lydia’s banking experience, community relationships, and proven ability to bring people together will help us understand local priorities, respond with purpose, and focus our resources where they can make the greatest impact.”

Ramirez brings nearly two decades of senior-level banking experience in strategic operations, sales management, client advocacy and team leadership, along with deep knowledge of the communities the bank serves. Her board service includes the Sacramento Hispanic Chamber of Commerce, Capital Black Chamber of Commerce, United Way California Capital Region, Valley Vision, Downtown Sacramento Partnership, Sacramento Food Bank & Family Services and the Sacramento Metropolitan Chamber Political Action Committee (Metro-PAC). She also serves on the advisory boards of the Sacramento State University College of Business Advisory Council and Creciente, a Latinx leadership program.

A 2021 Leadership Sacramento alumna and Class XXVI Senior Fellow of the American Leadership Forum, Ramirez earned bachelor’s degrees in psychology and Spanish from the University of California, Davis, and a Master of Business Administration degree from California State University, Sacramento. She is also a graduate of the California Bankers Association Executive Banking School.

Ramirez has been widely recognized for her leadership, including through honors from the Sacramento Business Journal’s 40 Under 40, Women Who Mean Business and Champions for DE&I; Comstock’s Magazine’s Women in Leadership; the Sacramento Bee’s inaugural Top 25 Latino Change Makers; the Association of Latino Professionals for America’s 50 Most Powerful Latinas; the National Association of Women Business Owners Sacramento Valley Chapter’s Outstanding Women Leaders; the Sac Cultural Hub Media Foundation’s Exceptional Women of Color Award; the Sacramento Hispanic Chamber of Commerce’s Champion Latina Estrella Award; the American Leadership Forum Mountain Valley Chapter’s Exemplary Leaders; and the California Hispanic Chambers of Commerce’s Minerva Empresaria Award.

About Five Star Bancorp
Five Star is a bank holding company headquartered in Rancho Cordova, California. Five Star operates through its wholly owned banking subsidiary, Five Star Bank. The bank has ten branches in California. For more information, visit https://www.fivestarbank.com.

Special Note Concerning Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements represent plans, estimates, objectives, goals, guidelines, expectations, intentions, projections, and statements of the Company’s beliefs concerning future events, business plans, objectives, expected operating results, and the assumptions upon which those statements are based. Forward-looking statements include without limitation, any statement that may predict, forecast, indicate, or imply future results, performance, or achievements, and are typically identified with words such as “may,” “could,” “should,” “will,” “would,” “believe,” “anticipate,” “estimate,” “expect,” “aim,” “intend,” “plan,” or words or phrases of similar meaning. The Company cautions that the forward-looking statements are based largely on the Company’s expectations and are subject to a number of known and unknown risks and uncertainties that are subject to change based on factors which are, in many instances, beyond the Company’s control. Such forward-looking statements are based on various assumptions (some of which may be beyond the Company’s control) and are subject to risks and uncertainties, which change over time, and other factors, which could cause actual results to differ materially from those currently anticipated. New risks and uncertainties may emerge from time to time, and it is not possible for the Company to predict their occurrence or how they will affect the Company. If one or more of the factors affecting the Company’s forward-looking information and statements proves incorrect, then the Company’s actual results, performance, or achievements could differ materially from those expressed in, or implied by, forward-looking information and statements contained in this press release. Therefore, the Company cautions you not to place undue reliance on the Company’s forward-looking information and statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, under the section entitled “Risk Factors,” and other documents filed by the Company with the Securities and Exchange Commission from time to time.

The Company disclaims any duty to revise or update the forward-looking statements, whether written or oral, to reflect actual results or changes in the factors affecting the forward-looking statements, except as specifically required by law.

Investor Contact:
Heather C. Luck, Chief Financial Officer
Five Star Bancorp
(916) 626-5008
hluck@fivestarbank.com

Media Contact:
Shelley R. Wetton, Chief Marketing Officer
Five Star Bancorp
(916) 284-7827
swetton@fivestarbank.com

COPENHAGEN, Denmark, Sept. 14, 2026 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND) today announced that its Board of Directors has authorized the Company to repurchase up to $400 million of the Company’s ordinary shares (the Share Repurchase Program).

Purchases under the planned Share Repurchase Program may be made from time to time, in such amounts as management deems appropriate, through a variety of methods, which may include open market purchases, privately negotiated transactions, block trades, accelerated share repurchase transactions, purchases through 10b5-1 trading plans, or by any combination of such methods. The timing and amount of any repurchases pursuant to the Share Repurchase Program will be determined based on market conditions, share price and other factors. The Share Repurchase Program does not require the Company to repurchase any specific number of shares, and may be modified, suspended or terminated at any time without notice.

About Ascendis Pharma A/S
Ascendis Pharma is a global biopharmaceutical company focused on applying our innovative TransCon technology platform to make a meaningful difference for patients. Guided by our core values of Patients, Science, and Passion, and following our algorithm for product innovation, we apply TransCon to develop new therapies that demonstrate best-in-class potential to address unmet medical needs. Ascendis is headquartered in Copenhagen, Denmark, and has additional facilities in Europe and the United States. Please visit ascendispharma.com to learn more.

Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis’ future operations, plans and objectives of management are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Examples of such statements include, but are not limited to, statements relating to (i) the planned Share Repurchase Program, including the timing, amount, and methods of any repurchases, (ii) Ascendis’ ability to apply its TransCon technology platform to make a meaningful difference for patients and (iii) Ascendis’ use of TransCon to develop new and potentially best-in-class therapies to address unmet medical needs. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including, without limitation: dependence on third‑party manufacturers, distributors, and service providers for Ascendis’ products and product candidates; risks related to regulatory review and approval, including the possibility of delays, requests for additional data or analyses, restrictions or limitations on use, approval with labeling that is more limited than expected, or failure to obtain approval in the United States, European Union, or other jurisdictions; clinical development risks, including that results from ongoing or future trials may not confirm earlier data; unforeseen safety or efficacy findings in development programs or on‑market products; manufacturing, supply chain, quality, or logistics issues that could delay development or commercialization; unforeseen expenses related to commercialization of any approved Ascendis products; unforeseen research and development or selling, general and administrative expenses and other costs impacting Ascendis’ business generally; market acceptance, pricing, and reimbursement challenges, including payer coverage decisions and health technology assessments; competitive developments, including new or improved therapies; intellectual property protection, freedom‑to‑operate, and litigation risks; Ascendis’ ability to obtain additional funding, if needed, to support its business activities; cybersecurity, data privacy, and information technology disruptions; and the impact of international economic, political, legal, compliance, public health, and business factors, including tariffs, trade policies, currency fluctuations, and geopolitical events. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis’ business in general, see Ascendis’ Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (SEC) on February 11, 2026, and Ascendis’ other future reports filed with, or submitted to, the SEC. Forward-looking statements do not reflect the potential impact of any future licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law.

Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo, and TransCon® are trademarks owned by the Ascendis Pharma Group. © September 2026 Ascendis Pharma A/S.

Investor Contact: Media Contact:
Chad Fugere Melinda Baker
Ascendis Pharma Ascendis Pharma
+1 (650) 519-7494 +1 (650) 709-8875

– All rights to TransCon technology-based products in metabolic and cardiovascular diseases, including once-monthly TransCon Semaglutide, will revert to Ascendis
–
Ascendis to initiate multiple programs in metabolic and cardiovascular diseases, including obesity

COPENHAGEN, Denmark, Sept. 14, 2026 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND) today announced that it will regain the exclusive rights to develop, manufacture, and commercialize TransCon technology-based products in metabolic and cardiovascular diseases, including obesity. This follows termination of the collaboration agreement between Ascendis and Novo Nordisk A/S announced in November 2024. Under the terms of the agreement, following termination all licenses granted to Novo Nordisk in metabolic and cardiovascular diseases, including for once-monthly TransCon Semaglutide, will revert to Ascendis, and neither party has any continuing financial obligations to the other.

Upon effective termination and reversion of rights, Ascendis plans to initiate multiple programs in both rare and large metabolic and cardiovascular indications, where it believes it can establish best-in-class therapies. These new programs include advancing once-monthly TransCon Semaglutide, an investigational long-acting prodrug of the GLP-1 receptor agonist semaglutide, as a potential treatment for obesity and type 2 diabetes.

“Our mission is to always make a meaningful difference for patients and Ascendis now plans to initiate multiple new programs in cardiovascular and metabolic diseases, including obesity, focusing where the unmet medical needs are greatest,” said Jan Mikkelsen, Ascendis Pharma’s President and Chief Executive Officer. “Our algorithm for product innovation has delivered three consecutive approved products and we are excited to apply our versatile TransCon platform with the same disciplined approach across these therapeutic areas, consistent with Vision 2030.”

About Ascendis Pharma A/S
Ascendis Pharma is a global biopharmaceutical company focused on applying our innovative TransCon technology platform to make a meaningful difference for patients. Guided by our core values of Patients, Science, and Passion, and following our algorithm for product innovation, we apply TransCon to develop new therapies that demonstrate best-in-class potential to address unmet medical needs. Ascendis is headquartered in Copenhagen, Denmark, and has additional facilities in Europe and the United States. Please visit ascendispharma.com to learn more.

Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis’ future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) the expected timing and effectiveness of the termination of the collaboration agreement with Novo Nordisk A/S and the reversion of rights to Ascendis, (ii) Ascendis’ plans to initiate multiple programs in metabolic and cardiovascular diseases, including obesity, (iii) the expected development and commercialization of once-monthly TransCon Semaglutide as a potential treatment for obesity and type 2 diabetes, (iv) Ascendis’ ability to establish best-in-class therapies in rare and large metabolic and cardiovascular indications, (v) Ascendis’ ability to apply its TransCon platform technology consistent with Vision 2030, and (vi) Ascendis’ use of its TransCon technology platform to develop new therapies that demonstrate best-in-class potential to address unmet medical needs. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including the following: unforeseen issues relating to the termination of the Novo Nordisk collaboration agreement, including potential disputes regarding the basis of termination or breach claims; dependence on third party manufacturers and distributors; unforeseen safety or efficacy results in TransCon Semaglutide or other development programs; unforeseen expenses related to development and potential commercialization of TransCon technology-based products in metabolic and cardiovascular diseases; delays in the development of TransCon Semaglutide or other development programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; and Ascendis’ ability to obtain additional funding, if needed, to support its business activities. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis’ business in general, see Ascendis’ most recent Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (SEC) and Ascendis’ other future reports filed with, or submitted to, the SEC. Forward-looking statements do not reflect the potential impact of any future licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law.
Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo, and TransCon® are trademarks owned by the Ascendis Pharma group. © September 2026 Ascendis Pharma A/S.

Investor Contacts:
Chad Fugere
Ascendis Pharma
+1 (650) 519-7494
  Media Contact:
Melinda Baker
Ascendis Pharma
+1 (650) 709-8875

Summer Field Program Advances Multiple Vein Targets Toward Planned 2026 Drilling

TORONTO, Sept. 14, 2026 (GLOBE NEWSWIRE) — Q-Gold Resources Ltd. (“QGold” or the “Company”) announces that its summer 2026 exploration program at the Mine Centre Gold Project returned select grab sample assays of up to 600 g/t gold and advanced multiple high-priority targets for the Company’s planned diamond drilling campaign later in 2026. Completing over three field rotations from June through August 2026, the program combined geological mapping, vein tracing, prospecting, grab sampling and systematic channel sampling across targets north and south of the historic Foley Mine. Assays have been received for the first two rotations, while assays from the third rotation remain pending.

HIGHLIGHTS

  • Select grab samples from the Ferguson Showing returned 600 g/t, 73.4 g/t, 57.8 g/t and 44.0 g/t gold along a northwest-striking vein approximately 500 m southwest of the historic Golden Star Mine (QG-AD-032, QG-AD-030, QG-ND-153 and QG-ND-051).
  • Grab samples from a quartz vein approximately 1.2 km south of the historic Manhattan Gold Vein Mine returned 46.6 g/t and 34.7 g/t gold (QG-ND-040 and QG-ND-039).
  • Select grab samples approximately 300 m south of the Foley Mine returned 95.1 g/t and 89.8 g/t gold within the broader Vowel, Jumbo and Bonanza multi-vein systems (QG-ND-125 and QG-AD-020).
  • The three-rotation program generated 222 grab samples and 126 channel samples, excluding quality-control samples, and will support target ranking for the planned 2026 drill campaign (all 126 channel sample assays and the remaining third-rotation grab sample assays are pending).

QGold is integrating the assay results with new geological mapping, vein tracing and structural measurements to rank drill targets across North Foley, South Foley, Nugget, Ferguson and Pacitto. The planned drilling campaign is expected to increase drill density around the previously drilled Foley Mine and test select surface targets identified by the 2026 program. Although certain veins in the area have been tested by historical drilling, most remain untested.

“The 2026 surface program has given us a broader and better-defined set of targets at Mine Centre,” said Dr. Andreas Rompel, Chief Operating Officer of QGold. “The high-grade grab sample results at Ferguson and South Foley warrant systematic follow-up. We will combine the pending channel assays with our mapping and structural data to prioritize the targets for the planned drill campaign.”

FIRST EXPLORATION ROTATION JUNE 22 TO JULY 6, 2026

Field crews completed systematic prospecting and grab sampling across the Foley Project, focusing on documented mineralized veins and showings. Assay highlights included 55.9 g/t gold at the Pacitto Showing, 32.1 g/t at the Government Vein, 23.2 g/t at the Daisy Vein, 34.7 g/t at the Nugget Vein, 9.61 g/t at the Twin Vein northeast of Foley and 6.66 g/t at the Zinc Vein northeast of Foley. These results guided the follow-up mapping and channel sampling completed during the subsequent rotations.

SECOND EXPLORATION ROTATION JULY 15 TO JULY 30, 2026

The second rotation followed up the mineralized zones identified during the initial program through geological mapping, prospecting, grab sampling and detailed examination of known vein systems. Assay highlights included 95.1 g/t gold at the South Foley Vein, 600 g/t at the northern end of the Government Vein within the Ferguson Showing and 73.4 g/t at the Daisy Vein within the Ferguson Showing. The field team used the results to refine the apparent extent and orientation of the mineralized structures and prioritize areas for channel sampling and future drilling.

THIRD EXPLORATION ROTATION AUGUST 13 TO AUGUST 26, 2026

The third rotation advanced the surface program through detailed geological mapping, vein tracing, channel sampling, grab sampling and structural measurements. Channel sampling and detailed channel sketches were completed across vein extensions at North Foley, high-grade South Foley follow-up targets, the Nugget Vein and the Government and Daisy veins within the Ferguson Showing. Crews also mapped and sampled newly identified or exposed portions of the vein systems. This work is intended to define the apparent continuity, geometry and extent of the gold-bearing veins and strengthen the geological basis for drill targeting. All channel sample assays and the remaining grab sample assays from this rotation are pending.

QGold 2026 Field Work Property Map.

Figure 1: QGold 2026 Field Work Property Map.

Foley Area Grab and Channel Samples Map.

Figure 2: Foley Area Grab and Channel Samples Map.

Ferguson and Pacitto Showings Grab and Channel Samples Map North of the Foley Mine.

Figure 3: Ferguson and Pacitto Showings Grab and Channel Samples Map North of the Foley Mine.

Table 1: QGold Channel Sample Results – 2026

Total samples: 126 (QC samples excluded). Coordinates are UTM Zone 15 easting/northing (m). “Pending” indicates assay results not yet received.

Sample ID Easting (m) Northing (m) Au (g/t)
QG-CL-001 525749 5394504 Pending
QG-CL-002 525749 5394504 Pending
QG-CL-003 525749 5394504 Pending
QG-CL-004 525749 5394504 Pending
QG-CL-005 525749 5394504 Pending
QG-CL-006 525749 5394504 Pending
QG-CL-007 525749 5394504 Pending
QG-CL-008 525749 5394504 Pending
QG-CL-009 525705 5394553 Pending
QG-CL-010 525705 5394553 Pending
QG-CL-011 525705 5394553 Pending
QG-CL-012 525705 5394553 Pending
QG-CL-013 525705 5394553 Pending
QG-CL-014 525705 5394553 Pending
QG-CL-015 525705 5394553 Pending
QG-CL-016 525705 5394553 Pending
QG-CL-017 525705 5394553 Pending
QG-CL-018 525692 5394609 Pending
QG-CL-019 525692 5394609 Pending
QG-CL-020 525692 5394609 Pending
QG-CL-021 525748 5394061 Pending
QG-CL-022 525748 5394061 Pending
QG-CL-023 525748 5394061 Pending
QG-CL-024 525789 5394057 Pending
QG-CL-025 525789 5394057 Pending
QG-CL-026 525789 5394057 Pending
QG-CL-027 525782 5394070 Pending
QG-CL-028 525782 5394070 Pending
QG-CL-029 525782 5394070 Pending
QG-CL-030 525838 5394197 Pending
QG-CL-031 525838 5394197 Pending
QG-CL-032 525838 5394197 Pending
QG-CL-033 525838 5394197 Pending
QG-CL-034 525822 5394176 Pending
QG-CL-035 525822 5394176 Pending
QG-CL-036 525822 5394176 Pending
QG-CL-037 526806 5395721 Pending
QG-CL-038 526806 5395721 Pending
QG-CL-039 526806 5395721 Pending
QG-CL-040 526806 5395721 Pending
QG-CL-041 526811 5395688 Pending
QG-CL-042 526811 5395688 Pending
QG-CL-043 526811 5395688 Pending
QG-CL-044 526811 5395688 Pending
QG-CL-045 526788 5395743 Pending
QG-CL-046 526788 5395743 Pending
QG-CL-047 526788 5395743 Pending
QG-CL-048 526788 5395743 Pending
QG-CL-049 526788 5395743 Pending
QG-CL-050 526788 5395743 Pending
QG-CL-051 526783 5395770 Pending
QG-CL-052 526783 5395770 Pending
QG-CL-053 526783 5395770 Pending
QG-CL-054 526783 5395770 Pending
QG-CL-055 526783 5395770 Pending
QG-CL-056 526726 5395818 Pending
QG-CL-057 526726 5395818 Pending
QG-CL-058 526726 5395818 Pending
QG-CL-059 526726 5395818 Pending
QG-CL-060 528080 5398367 Pending
QG-CL-061 528080 5398367 Pending
QG-CL-062 528080 5398367 Pending
QG-CL-063 528080 5398367 Pending
QG-CL-064 528096 5398365 Pending
QG-CL-065 528096 5398365 Pending
QG-CL-066 528096 5398365 Pending
QG-CL-067 528096 5398365 Pending
QG-CL-068 528117 5398359 Pending
QG-CL-069 528117 5398359 Pending
QG-CL-070 528117 5398359 Pending
QG-CL-071 528117 5398359 Pending
QG-CL-072 527969 5398483 Pending
QG-CL-073 527969 5398483 Pending
QG-CL-074 527969 5398483 Pending
QG-CL-075 527969 5398483 Pending
QG-CL-076 527969 5398483 Pending
QG-CL-077 527969 5398483 Pending
QG-CL-078 527969 5398483 Pending
QG-CL-079 527969 5398483 Pending
QG-CL-080 527969 5398483 Pending
QG-CL-081 528004 5398417 Pending
QG-CL-082 528004 5398417 Pending
QG-CL-083 528004 5398417 Pending
QG-CL-084 528004 5398417 Pending
QG-CL-085 528004 5398417 Pending
QG-CL-086 528004 5398417 Pending
QG-CL-087 528004 5398417 Pending
QG-CL-088 528004 5398417 Pending
QG-CL-089 528004 5398417 Pending
QG-CL-090 528004 5398417 Pending
QG-CL-091 528004 5398417 Pending
QG-CL-092 528042 5398380 Pending
QG-CL-093 528042 5398380 Pending
QG-CL-094 528042 5398380 Pending
QG-CL-095 528042 5398380 Pending
QG-CL-096 527949 5398549 Pending
QG-CL-097 527949 5398549 Pending
QG-CL-098 527949 5398549 Pending
QG-CL-099 527949 5398549 Pending
QG-CL-100 527925 5398634 Pending
QG-CL-101 527925 5398634 Pending
QG-CL-102 527925 5398634 Pending
QG-CL-103 527925 5398634 Pending
QG-CL-104 527936 5398663 Pending
QG-CL-105 527936 5398663 Pending
QG-CL-106 527936 5398663 Pending
QG-CL-107 527936 5398663 Pending
QG-CL-108 528080 5398484 Pending
QG-CL-109 528080 5398484 Pending
QG-CL-110 528080 5398484 Pending
QG-CL-111 528080 5398484 Pending
QG-CL-112 528116 5398472 Pending
QG-CL-113 528116 5398472 Pending
QG-CL-114 528116 5398472 Pending
QG-CL-115 528071 5398491 Pending
QG-CL-116 528071 5398491 Pending
QG-CL-117 528071 5398491 Pending
QG-CL-118 528020 5398500 Pending
QG-CL-119 528020 5398500 Pending
QG-CL-120 528020 5398500 Pending
QG-CL-121 528193 5398461 Pending
QG-CL-122 528193 5398461 Pending
QG-CL-123 528193 5398461 Pending
QG-CL-124 528254 5398411 Pending
QG-CL-125 528254 5398411 Pending
QG-CL-126 528254 5398411 Pending

Table 2: QGold Grab Sample Results – 2026
Total samples: 222 (QC samples excluded). Coordinates are UTM Zone 15 easting/northing (m). Au reported in g/t; “Pending” indicates assay results not yet received.

Sample ID Easting (m) Northing (m) Au (g/t)
QG-ND-001 525656 5393698 0.007
QG-ND-002 525607 5393741 1.67
QG-ND-003 525577 5393817 0.488
QG-ND-004 525602 5394414 0.29
QG-ND-005 525594 5394436 0.045
QG-ND-006 525629 5394669 0
QG-ND-007 525629 5394672 0.008
QG-ND-008 525527 5394646 0.631
QG-ND-009 525525 5394667 0.313
QG-ND-010 525568 5393707 0
QG-ND-011 525569 5393725 0
QG-ND-012 525736 5393585 0.025
QG-ND-013 525727 5393585 0.008
QG-ND-014 525697 5394247 0.175
QG-ND-015 525728 5394246 2.4
QG-ND-016 525729 5394252 0.772
QG-ND-017 525729 5394245 0.021
QG-ND-018 526295 5394764 1.11
QG-ND-019 526292 5394771 9.61
QG-ND-020 526297 5394760 0.073
QG-ND-021 526290 5394769 1.77
QG-ND-022 526318 5394820 0.023
QG-ND-023 526290 5394867 0.592
QG-ND-024 526278 5394880 0.898
QG-ND-025 526261 5394894 1.13
QG-ND-026 526201 5394921 2.01
QG-ND-027 526171 5394956 6.66
QG-ND-028 526575 5394910 8.38
QG-ND-029 526544 5394975 0.278
QG-ND-030 526537 5395004 0.326
QG-ND-031 526451 5395241 0.162
QG-ND-032 526424 5395364 0.083
QG-ND-033 526408 5395370 5.61
QG-ND-034 526382 5395380 0.071
QG-ND-035 526353 5395389 13.6
QG-ND-036 526308 5395408 0.019
QG-ND-037 526806 5395719 20
QG-ND-038 526806 5395719 8.41
QG-ND-039 526820 5395692 34.7
QG-ND-040 526824 5395682 46.6
QG-ND-041 527929 5398000 1.9
QG-ND-042 527906 5398217 0.451
QG-ND-043 527975 5398122 0.082
QG-ND-044 528151 5398342 22
QG-ND-045 528130 5398350 5.75
QG-ND-046 528115 5398357 0.063
QG-ND-047 528078 5398366 32.1
QG-ND-048 528042 5398379 0.016
QG-ND-049 527986 5398445 0.017
QG-ND-050 527975 5398459 0.124
QG-ND-051 528081 5398477 44
QG-ND-052 528179 5398449 23.2
QG-ND-053 528246 5398417 2.54
QG-ND-054 528128 5399030 2.76
QG-ND-055 527844 5399038 0.386
QG-ND-056 527655 5398891 0
QG-ND-057 527732 5398821 0
QG-ND-058 527625 5398867 0.015
QG-ND-059 527625 5398864 0
QG-ND-060 527610 5398893 0.08
QG-ND-061 527599 5398917 0.018
QG-ND-062 527600 5398951 0
QG-ND-063 527465 5398636 0.033
QG-ND-064 527469 5398640 0
QG-ND-065 527475 5398617 0.151
QG-ND-066 525764 5395209 2.26
QG-ND-067 525759 5395216 1.28
QG-ND-068 525583 5395648 0
QG-ND-069 525555 5395788 0
QG-ND-070 525449 5395471 0
QG-ND-071 523505 5392484 0.007
QG-ND-072 523486 5392479 0
QG-ND-073 523468 5392467 0.07
QG-ND-074 523431 5392586 0.056
QG-ND-075 523422 5392574 2.44
QG-ND-076 523410 5392566 0.43
QG-ND-077 523410 5392566 0.129
QG-ND-078 523480 5392434 0.02
QG-ND-079 523367 5392394 0.029
QG-ND-080 523372 5392394 0.012
QG-ND-081 523390 5392393 0.01
QG-ND-082 523186 5392367 0
QG-ND-083 528756 5399646 0.045
QG-ND-084 528790 5399602 0
QG-ND-085 528946 5399627 55.9
QG-ND-086 528950 5399626 23.2
QG-ND-087 529028 5399604 0.062
QG-ND-088 529025 5399593 0.007
QG-ND-089 529165 5399642 0.009
QG-ND-090 525705 5394553 0.529
QG-ND-091 525700 5394573 0.142
QG-ND-092 525780 5394984 0.028
QG-ND-093 523946 5392045 <0.005
QG-ND-094 523940 5392012 0.038
QG-ND-095 527206 5397925 <0.005
QG-ND-096 527259 5397932 <0.005
QG-ND-097 527115 5398109 0.065
QG-ND-098 527111 5398122 0.017
QG-ND-099 527113 5398124 1.44
QG-ND-100 527166 5397669 0.018
QG-ND-101 526643 5395154 0.007
QG-ND-102 526631 5395194 0.039
QG-ND-103 526601 5395169 3.53
QG-ND-104 526610 5395255 0.007
QG-ND-105 526624 5395226 0.691
QG-ND-106 526627 5395256 0.232
QG-ND-107 526650 5395249 7.38
QG-ND-108 526640 5395260 4.6
QG-ND-109 526620 5395275 5.69
QG-ND-110 522681 5398969 0.515
QG-ND-111 522574 5398970 <0.005
QG-ND-112 522667 5398985 <0.005
QG-ND-113 522669 5398981 <0.005
QG-ND-114 522689 5398973 0.336
QG-ND-115 525748 5394509 0.387
QG-ND-116 525748 5394509 0.381
QG-ND-117 525217 5395001 <0.005
QG-ND-118 524942 5394927 0.093
QG-ND-119 524723 5394515 0.016
QG-ND-120 522940 5392547 0.832
QG-ND-121 522940 5392549 0.279
QG-ND-122 522941 5392526 0.317
QG-ND-123 522941 5392523 <0.005
QG-ND-124 522942 5392519 0.006
QG-ND-125 525747 5394069 95.1
QG-ND-126 525734 5393957 11.4
QG-ND-127 525781 5394075 1.53
QG-ND-128 525789 5394059 23.5
QG-ND-129 525776 5394067 0.056
QG-ND-130 526699 5395481 0.011
QG-ND-131 526698 5395484 0.012
QG-ND-132 526737 5395440 25
QG-ND-133 525792 5394039 10.1
QG-ND-134 525790 5394039 0.061
QG-ND-135 528830 5399606 0.019
QG-ND-136 528943 5399627 17.3
QG-ND-137 528940 5399627 14.2
QG-ND-138 528894 5399629 1.16
QG-ND-139 528886 5399638 5.98
QG-ND-140 528884 5399640 0.249
QG-ND-141 528275 5398406 53.5
QG-ND-142 528270 5398410 0.285
QG-ND-143 528261 5398410 10.3
QG-ND-144 528250 5398412 15
QG-ND-145 528235 5398424 6.82
QG-ND-146 528224 5398429 3.39
QG-ND-147 528452 5399526 0.012
QG-ND-148 528192 5398449 0.032
QG-ND-149 528170 5398455 28.8
QG-ND-150 528060 5398486 21.4
QG-ND-151 528045 5398491 6.6
QG-ND-152 528025 5398497 2
QG-ND-153 528017 5398501 57.8
QG-ND-154 528007 5398496 0.674
QG-ND-155 527974 5398507 0.196
QG-ND-156 527983 5398526 4.02
QG-ND-157 527951 5398547 38.3
QG-ND-158 527953 5398547 8.83
QG-ND-159 528015 5398822 0.03
QG-ND-160 527934 5398978 0.022
QG-ND-161 529077 5399617 0.457
QG-ND-162 529079 5399621 0.274
QG-ND-163 529389 5399645 <0.005
QG-ND-164 526788 5395744 Pending
QG-ND-165 526784 5395737 Pending
QG-ND-166 526774 5395752 Pending
QG-ND-167 526774 5395754 Pending
QG-ND-168 526757 5395783 Pending
QG-ND-169 526733 5395807 Pending
QG-ND-170 525697 5394609 Pending
QG-ND-171 525572 5394840 Pending
QG-ND-172 525572 5394840 Pending
QG-ND-173 525823 5394165 Pending
QG-ND-174 525828 5394177 Pending
QG-ND-175 528190 5398317 Pending
QG-ND-176 528066 5398373 Pending
QG-ND-177 528016 5398400 Pending
QG-ND-178 528017 5398400 Pending
QG-ND-179 527918 5398210 Pending
QG-ND-180 527905 5398221 Pending
QG-ND-181 527906 5398218 Pending
QG-ND-182 528221 5399008 Pending
QG-ND-183 528205 5398979 Pending
QG-ND-184 527875 5398244 Pending
QG-ND-185 527873 5398244 Pending
QG-ND-186 527870 5398245 Pending
QG-ND-187 527862 5398254 Pending
QG-ND-188 527836 5398270 Pending
QG-AD-001 525700 5394562 0.231
QG-AD-002 523556 5391610 <0.005
QG-AD-003 523554 5391608 0.012
QG-AD-004 527298 5397153 0.379
QG-AD-005 527292 5397160 3.51
QG-AD-006 527297 5397157 0.033
QG-AD-007 527305 5397146 5.99
QG-AD-008 522590 5399438 0.011
QG-AD-009 522589 5399440 1.31
QG-AD-010 522214 5399260 0.11
QG-AD-011 522214 5399259 0.015
QG-AD-012 525751 5394507 0.272
QG-AD-013 525207 5394648 <0.005
QG-AD-014 522970 5392326 0.007
QG-AD-015 522704 5392373 0.031
QG-AD-016 522653 5392447 0.169
QG-AD-017 522652 5392446 0.124
QG-AD-018 525751 5393983 0.078
QG-AD-019 525728 5393968 0.007
QG-AD-020 525832 5394098 89.8
QG-AD-021 526699 5395479 0.011
QG-AD-022 526701 5395477 0.01
QG-AD-023 526740 5395434 0.588
QG-AD-024 528839 5399599 0.009
QG-AD-025 528881 5399598 0.128
QG-AD-026 528108 5398466 17.8
QG-AD-027 528067 5398486 1.03
QG-AD-028 528093 5398463 0.045
QG-AD-029 527931 5398597 26.4
QG-AD-030 527931 5398597 73.4
QG-AD-031 527930 5398655 2.16
QG-AD-032 527925 5398659 600
QG-AD-033 528096 5398361 13.3
QG-AD-034 528930 5399696 0.775

                                                                                                                          

About Q-Gold Resources Ltd

Q-Gold Resources Ltd. is a Canadian gold development and exploration company focused on advancing high-quality gold assets in North America. The Company is led by the Quartz Mountain Gold Project in Oregon, USA – a large-scale gold development project with strong economics, long-term scalability and district-scale exploration potential.

QGold remains focused on disciplined project advancement, responsible resource development and long-term shareholder value creation through the development and exploration of high-quality North American gold assets.

Quality Assurance and Quality Control

QGold implemented a strict QA/QC protocol during the 2026 summer field sampling program. A rotating sequence of certified gold standards, blanks, and crush duplicates was inserted after every 20th field sample to monitor the accuracy and precision of the analytical results. All samples were collected, documented, and handled under the supervision of the project geologist.

Field samples were placed in sturdy plastic sample bags, labelled with the appropriate sample identification, and securely sealed using zip ties. Sample numbers, locations, geological descriptions, and other relevant field information were recorded and entered into the project database. Samples were securely stored in rice bags prior to transportation.

Following completion of each field rotation, the sealed sample bags were placed into rice bags, secured, and transported by company personnel to the Activation Laboratories Ltd. (“Actlabs”) laboratory facility in Dryden, Ontario, for analysis. Samples were delivered under controlled chain-of-custody procedures and remained secured under the supervision of the project geologist until shipment.

Samples were processed and crushed at the Actlabs facility. Gold analyses were completed using a 50-gram Fire Assay with Atomic Absorption finish. Samples were also analyzed for trace element geochemistry using the UT-4M ultratrace method with 4-Acid Digest and ICP-OES/ICP-MS finish. The inserted blanks, certified standards, and crush duplicates were used to monitor laboratory performance and verify the reliability of the reported analytical results.

Analyses were completed at Actlabs, located in Dryden, Ontario. Actlabs is accredited to ISO/IEC 17025 for mineral analysis (CAN-P-1579) and is ISO 9001 certified. Actlabs is independent of QGold and has no other relationship with the Company.

Grab samples are selective by nature and may not be representative of the overall mineralization hosted on the property.

Qualified Person

The scientific and technical information contained in this news release has been reviewed and approved by Jason Arnold, P.Geo., an independent consultant who is a “qualified person” within the meaning of National Instrument 43-101 – Standards of Disclosure for Mineral Projects.

For Further Information:

Peter Tagliamonte
Chairman & Chief Executive Officer
Cell: +1 (416) 564-2880
Q-Gold Resources Ltd.
info@qgoldresources.com | www.qgoldresources.com

Cautionary Statements

This press release contains forward-looking statements, including, but not limited to, statements regarding the Company’s planned 2026 diamond drilling campaign at the Mine Centre Gold Project; the receipt, timing and interpretation of pending assay results; the use of mapping, sampling and structural data to identify, delineate and prioritize exploration targets; future drilling and exploration results; project advancement; corporate objectives; and plans to advance the Company’s gold exploration and development platform. Forward-looking statements are based on management’s current expectations, assumptions and beliefs and are subject to known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those expressed or implied by such statements, including but not limited to: receipt of necessary approvals; general business, economic, competitive, political and social uncertainties; future mineral prices and market demand; accidents, labour disputes and shortages; and other risks of the mining industry. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate and actual results and future events may differ materially from those anticipated in such statements. Readers are cautioned not to place undue reliance on forward-looking statements. The Company undertakes no obligation to update or revise any forward-looking statements except as required by applicable securities laws.

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/7c21e64e-0501-4a5a-8ae3-6aa7e354140c

https://www.globenewswire.com/NewsRoom/AttachmentNg/4a36d834-f153-4394-a754-2c2ed2844727

https://www.globenewswire.com/NewsRoom/AttachmentNg/0b560451-f9d5-456b-acae-61888e1ab53f

CONWAY, Ark., Sept. 14, 2026 (GLOBE NEWSWIRE) — Home BancShares, Inc. (NYSE: HOMB), parent company of Centennial Bank, today announced it expects to release Third Quarter 2026 earnings after the market closes on October 14, 2026. Following this release, management will conduct a conference call to review these earnings at 1:00 p.m. CT (2:00 p.m. ET) on Thursday, October 15, 2026.

We strongly encourage all participants to pre-register for the conference call webcast or the live call using one of the following links. First, participants can pre-register for the conference call webcast using the following link:  https://events.q4inc.com/attendee/887189816. Participants who pre-register will be given a unique webcast link to gain immediate access to the conference call webcast. Second, participants can pre-register for the live call using the following link: https://events.q4inc.com/analyst/887189816?pwd=Khijd6H0. Participants who pre-register will be given the phone number and unique access codes to gain immediate access to the live call. Participants may pre-register now, or at any time prior to the call, and will immediately receive simple instructions via email. The Home BancShares conference call will also be scheduled as an event in your Outlook calendar.

Those without internet access or unable to pre-register may dial in and listen to the live call by calling 1-833-461-5787, Passcode: 887189816. A replay of the call will be available using the following link: https://events.q4inc.com/attendee/887189816. Internet access to the call will be available live or in recorded version on the Company’s website at www.homebancshares.com.

Home BancShares, Inc. is a bank holding company, headquartered in Conway, Arkansas. Its wholly-owned subsidiary, Centennial Bank, provides a broad range of commercial and retail banking plus related financial services to businesses, real estate developers, investors, individuals and municipalities. Centennial Bank has branch locations in Arkansas, Florida, Texas, Tennessee, South Alabama and New York City. The Company’s common stock is traded through the New York Stock Exchange under the symbol “HOMB.”

FOR MORE INFORMATION CONTACT:

Home BancShares, Inc.
Donna Townsell
Senior Executive Vice President &
Director of Investor Relations
(501) 328-4625
Ticker symbol: HOMB

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.